Deputy Nguyen Lan Hieu, director of Hanoi Medical University Hospital, told the National Assembly on 3 November that many drugmakers only change salt forms, formulations or dosages to win new patents and extend exclusivity beyond the usual protection period of about 20 years. This “evergreening” can delay cheaper generics reaching patients, so he proposed that changes without a significant improvement in treatment efficacy not be deemed inventive. He also proposed that Vietnamese firms be allowed to research, test and file for generic registration while the original patent remains in force, as otherwise they could wait 2–3 years before selling. On AI, he suggested that products created by AI without meaningful human creative input not receive copyright protection, and warned that Vietnamese medicinal plants could be taken abroad, patented and returned to the domestic market.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Nhiều hãng dược kéo dài độc quyền, nguy cơ thuốc giá rẻ chậm đến tay người bệnh
Keywords
pharmaceuticalsregulationartificial intelligence
Open a keyword to see other news on the same topic.
Related tickers and likely impact
IMP
▼ Likely negativeImexpharm Pharma
Relevance: low
| Market | Vietnam stocks |
|---|---|
| Exchange | HOSE |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Market cap | 5,514 bn VND |
| P/E | 15.0 |
| P/B | 2.27 |
| Close on 11/02/2026 | 35.00 |
| Change that session | -2.23% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Clarivate to Bring Trusted Trademark Data into Microsoft Copilot Through IPOne
Clarivate announced it will bring trusted CompuMark trademark data and insights into Microsoft Copilot through its IPOne connector, letting intellectual property professionals query and analyze this intelligence in natural language and through AI agents within the tools they already use. Simon Webster, Clarivate's President of Intellectual Property, said the collaboration advances the IPOne vision of bringing trusted IP intelligence into daily workflows. Microsoft's Chantrelle Nielsen said the integration gives IP professionals access to trademark intelligence through natural language and lets them build it into agentic workflows. IPOne is being developed with corporate IP teams at 15 Fortune 500 companies and leading law firms.
- New bipartisan bill aims to speed up clinical trials for rare disease treatments
Bipartisan Reps. Jake Auchincloss (D) and Morgan Griffith (R) introduced the "Faster Clinical Trials Act" to speed up studies of rare disease treatments, one week after the FDA unveiled a new initiative for these drugs. The bill would create a network of reusable clinical trial sites and a "Center for Clinical Trial Innovation" at the FDA, with up to $75 million in annual funding over five years. Its goal is to cut trial costs and enrollment time by at least 30%, and to let patients receive experimental drugs at their regular doctor's office, with progress tracked through Zoom, electronic health records or wearables. Griffith said this would also help patients who live hours away from medical centers.
- Amazon.com (AMZN) Received An FDA Warning Over Unapproved STI Drug Listings
On October 15, 2026, Amazon.com (AMZN) received an FDA warning letter over unapproved drug products for sexually transmitted infections. The FDA cited several marketplace listings marketed as treatments or cures without required drug approvals and warned that continued sales could lead to product seizures or injunctions if the issues are not corrected. The article views this as a test of Amazon's marketplace controls and platform governance rather than its AI growth story, and says the company's disclosures and future FDA updates will be the clearest measure of the impact.
- US delays small imports rule that raised alarm over prescription drug costs
- ‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The Federal Trade Commission and seven states have asked that Martin Shkreli be held in contempt. Shkreli is in trouble with regulators again, this time for allegedly influencing biopharma stocks.
- Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim
The FTC and seven states asked a federal judge to hold Martin Shkreli in contempt, alleging he repeatedly violated a 2022 civil order that banned him for life from the pharmaceutical industry. Since his release from prison in May 2022, they say, he has traded pharma stocks and publicly commented on the management of many drug companies. FTC Commissioner Mark Meador said escalating penalties, including fines and possibly incarceration, are warranted. The order stemmed from a finding that Shkreli orchestrated an anti-competitive scheme to protect his monopoly on the anti-parasitic drug Daraprim, raising its price from $17.50 to $750 per pill, and it also required him to disgorge more than $64 million. The FTC's Daniel Guarnera stressed that defendants must fulfill court orders and the agency will enforce violations.
Related markets
Latest news
- Five rate hikes in 10 months: one country lifts interest rates to 18-year high to fight inflation
The Reserve Bank of Australia (RBA) raised its cash rate by 25 basis points to 4.85%, the highest since November 2008 and its fifth hike in 2026. The decision passed 6–3, reflecting divided views on the board. September CPI rose 4.3% year on year, up from 4% in August, and the RBA expects inflation to stay elevated through most of 2027, returning to the 2–3% target only by late 2027, three quarters later than previously forecast. Q2 GDP growth slowed to 2.1% year on year from 2.5% in Q1. Governor Michelle Bullock said a recession is not the central scenario.
- Entergy Corp (ETR) Q3 2026 Earnings Call Highlights: Strong EPS, Google Expansion, and a ...
Entergy Corp (ETR) reported Q3 2026 adjusted EPS of $1.98, driven by a hot summer and strong residential and industrial sales. It narrowed its 2026 adjusted EPS guidance range, raising the bottom by $0.10, and expects an EPS growth trajectory above 8%. The capital plan for 2027–2030 rose by about $1.5 billion, including roughly $600 million for the Google expansion, and the Google service agreement was expanded to add at least $500 million in customer bill savings, bringing the total to at least $7.5 billion. Management also cited higher O&M and interest expense, rising labor and material costs, and about $1.4 billion of transmission investment not yet added pending regulatory approval for the Entergy Louisiana transaction.
- 72 Vietnamese firms make Top 500 Southeast Asia list; Deputy Minister Le Tan Can: 'We hope foreign investors don't just see Vietnam as a production site'
Speaking at the Fortune Southeast Asia 500 Summit, Deputy Finance Minister Le Tan Can said Vietnam's GDP grew 9.01% in the first nine months of 2026 and that the country is consolidating its position among ASEAN's top four economies. He said Vietnam is shifting toward growth driven by productivity, quality and high value added, with the private sector as the most important engine. He outlined five areas of cooperation for foreign investors: joint R&D and technology commercialisation, investment in priority sectors such as semiconductors, AI and clean energy, deeper linkages with domestic firms in value chains, high-quality human resources, and participation in building an international financial centre. He hoped foreign firms would see Vietnam not only as an investment location, production base or market, but also as a partner in research and innovation.
- Vietcombank receives State Bank approval to raise charter capital by VND 5,431 billion
The State Bank of Vietnam has approved Vietcombank (VCB) raising its charter capital by up to VND 5,431 billion through a private placement to professional securities investors. If fully issued, charter capital would rise from VND 83,557 billion to about VND 88,988 billion. The placement covers up to 6.5% of outstanding shares, about 543.1 million shares, a plan dating from 2019 that has not yet been completed; the chairman said Mizuho will participate. In Q3 2026, pre-tax profit was VND 11,218 billion, flat year on year, as credit provision expenses rose to VND 6,184 billion, nearly 8 times the prior-year level; nine-month pre-tax profit reached VND 40,440 billion, up 22%. As of 30 September 2026, non-performing loans were VND 12,818 billion, the NPL ratio was 0.71% and the coverage ratio was 243%.
- Brokerage CEO on what matters more than how many points the VN-Index gains
Nguyễn Duy Linh, CEO of SHS, said that after 30 years, the market capitalisation of stocks on HOSE, HNX and UPCoM exceeded VND 10.57 million billion, equal to 82.3% of estimated 2025 GDP, with average daily trading value near VND 29,300 billion. Securities accounts reached nearly 14.1 million, and the market was upgraded to FTSE Russell's secondary emerging market status on 21 September 2026. Linh said the next phase should focus on quality over scale, including better corporate quality, more efficient capital allocation, and a shift from short-term capital flows to long-term funding. He also stressed the need for more capable intermediary financial institutions.
- From 15 November, foreign organisations that want to recruit Vietnamese workers must do one thing
Decree No. 371/2026/ND-CP, dated 25 September 2026 and effective 15 November 2026, sets out detailed rules on recruiting and managing Vietnamese workers employed by foreign organisations and individuals in Vietnam. A foreign employer must notify the management agency in writing, in person, by post or online, stating the positions and number of workers needed, and publicly post the vacancy on the national employment exchange, another lawful job portal or its official website. Within 10 working days after signing an employment contract, the employer must notify the agency, and the worker must submit a personnel file within the same period. When the contract ends, the employer must notify the agency within 10 working days, stating the reason, and the agency must confirm within 3 working days.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.